CORAL GABLES, FL / ACCESSWIRE / November 12, 2018 / New trends in Healthcare have helped push biotechnology stocks and healthcare stocks higher this year. One of the larger trends has been with the technology side of this ever-expanding industry. Connected health is a new model for healthcare delivery, which provides healthcare services remotely.
Connected healthcare solutions amalgamate data from various sources to provide a holistic picture of an individual's health. According to reports* the global connected healthcare market is expected to reach $105,337.5 Million by 2022 at a CAGR of 30.27% during the forecast period.
M-health services, accounted for the largest share of the U.S. connected healthcare market, registering revenue of USD 1.95 billion in 2015 and expected to reach USD 16.33 billion by 2022. It also accounts for the largest market segment in UK, Italy, Japan China, and India. Germany accounted for the largest market share of Europe connected healthcare market registering revenue of USD 946.5 million in 2015, and is expected to reach USD 7.99 billion by 2022. Companies looking to take advantage of new healthcare industry trends include Premier Health Group, Inc. (PHGRF) (PHGI), Lannett Company, Inc. (LCI) and ReShape Lifesciences Inc. (RSLS)
Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. The company has recently seen market activity that is higher than average and could be attributed to the company's most recent announcements.
Premier Health Group, Inc. (PHGRF) (PHGI) announced last week that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company. ''Pharmacy is a critical component in our commitment to providing patients with best in class primary care that is accessible and efficient in its delivery. Having the ability to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients with ease, and having it as a part of our comprehensive technology solution for primary care, is something we are very excited to roll-out to patients,'' said Dr. Essam Hamza, CEO of Premier.
The Company is actively reviewing a pipeline of additional pharmacy partners which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies. The Canadian retail pharmacy market is estimated to be $44 billion (Source:IBISWorld). It is expected the industry sector will continue to allow for favorable economics for pharmacy operators as baby boomer's demand increases for prescriptions and operators expand the scope of practice to include preventative services.
Lannett Company, Inc. (LCI) announced today that it has entered into an agreement with Amneal Pharmaceuticals, Inc. with regard to Levothyroxine Sodium Tablets USP. Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers. Lannett will receive an upfront payment of $50 million, other terms of the transaction were not disclosed.
"This agreement benefits all parties, including and importantly patients and customers who can be assured of a definitive transition and supply plan for this important medication," said Tim Crew, chief executive officer of Lannett. "For Lannett, this transaction guarantees $50 million of gross profit, which exceeded our previous projections for the 16 week period."
Shares of LCI hit highs of $6.35 during premarket trading on Monday.
ReShape Lifesciences Inc. (RSLS) a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company announced today that on November 7, 2018 the company conducted an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The investigator meeting took place in Frankfurt, Germany and was intended to further establish relationships with the study team and to prepare investigators for the upcoming clinical trial for the ReShape Vest.
"I am glad to have participated in the well-attended European investigators meeting to discuss the European study of the novel Reshape Vest," stated Professor Martin Fried, MD, PhD, Head of OB Klinka Center for Treatment of Obesity and Metabolic Disorders in Prague, Czech Republic. "The early Gastric Vest clinical study from Mexico is very promising and we are excited about the outcomes. We look forward to starting the study in 2019 in the Czech Republic."
The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight.
Shares of ReShape surged as high as $7.32 before 10:30AM EST on Monday.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
*Digital Journal Report: http://www.digitaljournal.com/pr/4021709